

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

THE BINDING OF GLYCOSAMINOGLYCANS TO PEPTIDES

A thesis presented in partial fulfilment
of the requirements for the degree of
Master of Science in Biochemistry
at Massey University

GRANT JOHN TAYLOR
1994

ABSTRACT

The overall aim this study was to examine the possibility of using immobilised polypeptide chains to fractionate/separate Glycosaminoglycans (GAG's) from mixtures.

Initially individual samples of three GAG classes (chondroitin sulphate, dermatan sulphate and heparin) were characterised to establish purity and provide basic information. Once these samples had been characterised the samples were treated as standards.

Three short poly-l-lysine (PLL) chains with defined length and orientation were synthesized. As a control a PLL chain with 633 residues was immobilised. The interaction of the GAG standards with these resins did not replicate published solution binding behaviour of longer PLL chains. This suggested a different mode of binding. The interaction of two lengths of PLL (126 and 633 residues) and the K₈G peptide with the GAG standards in solution was investigated. These studies demonstrated that the mode of binding of GAG's to short PLL chains was radically different to the earlier reported solution binding studies. β -Strand dominates with the short PLL chains instead of α -helix established in the published solution binding studies.

The interaction of two peptides PCI (264-283) and thrombospondin peptide with the GAG standards was studied using circular dichroism spectroscopy. In the case of the PCI peptide, each GAG induced different secondary structures. Chondroitin sulphate and heparin induced an α -helix, whereas dermatan sulphate gave β -strands. Heparin and dermatan sulphate induced double the amount of secondary structure compared to chondroitin sulphate. The strength of the interaction of GAG's with the peptide was also measured by the concentration of salt required to dissociate 50% of the complex. The figures for dermatan sulphate and heparin were found to be 0.1 and 0.3 M salt respectively. The binding of the GAG standards to the thrombospondin

peptide did not elicit any detectable change in conformation of the peptide.

Critical examination of published material on the interaction of GAG's (principally heparin) with short peptides, prompted the writer to propose two **new** complementary models. The first model examines binding in terms of the conformation of the peptide induced by binding to the GAG. It is composed of three components, the periodicity of polar and nonpolar residues within the peptide sequence, the spacing of pairs of basic residues and the spacing of pairs of acidic and basic residues. This model is successfully able to rationalise the binding behaviour of a number of GAG/peptide interactions in terms of the dominant secondary structure and the biological activity. The model is able to make a number of specific predictions. The second model examines the strength of the interaction between heparin and peptides containing the proposed consensus sequences for GAG binding sites. A significant correlation between the binding strength and an attribute derived from the sequence of the peptide was found using only one assumption. The assumption was that the peptides in the correlation bound to heparin with significant levels of β -strand.

For the **first time** it is possible to rationalise the behaviour of GAG/peptide interactions in a coherent manner. The design of peptides that are capable of binding to specific GAG's now seems possible.

This thesis is dedicated to the most unappreciated group of chemicals in the science of biochemistry: glycosaminoglycans. Thanks to my long suffering laboratory companions: Simon Burton, Lou Wen and Estela Campanella (a.k.a dancing in the streets). I can honestly say that it has certainly been an experience. Thanks to my supervisor David Harding for his support and intellectual contribution, at several critical points in the research project and the drafting of the thesis. Thanks to Darren Englebretsen (a.k.a. Dr Cellulose) and Jenny Cross of the former SSU for helpful advice on peptide synthesis and the synthesis of three peptides. Thanks to Marcia Baker of the Separation Science Programme (formerly the Separation Science Unit) for looking after the finances of the project. It is with regret that I must acknowledge the demise of the SSU, that supplied the intellectual climate in which enabled this project to be fostered. I hope that the unique climate will be allowed to continue to exist by the powers that be.

Thanks to Rod Mackenzie and Carol Flyger of the Chemistry and Biochemistry Department of Massey University for calcium, A.A.S analysis and amino acid analysis respectively. Thanks to John Hastie and Ken Jolley of the Physics and Biophysics Department of Massey University for C¹³ NMR analysis of GAG standards. Thanks to Duncan MaKay and Selwyn Yorke of New Zealand Pharmaceuticals (NZP) for advice on GAG electrophoresis and supplying GAG samples respectively. Thanks to Gavin Manderson and Laurie Creamer of the protein separation section of the Dairy Research Institute for advice on the use of the CD instrument.

To my friends Paul and Linda Hoek, Philip Howard and Marie Wong for their friendship, support and encouragement over the years, I owe you all a debt of gratitude which I can never repay. Heartfelt appreciation to Alicia Pogoni and Dianna Elliott for dispensing fermented malt beverages and stimulating conversations during many evenings while I was writing this thesis. Finally I would like to thank NZ FORST for the financial support of this project, through NZP. It was greatly appreciated.

Abstract	ii
Acknowledgements	iv
Table of Contents	v
List of Figures	x
List of Tables	xi
List of Abbreviations	xiv
Chapter 1: Introduction	1
1.1 REVIEW OF GLYCOSAMINOGLYCANS STRUCTURE AND FUNCTION	1
1.1.1 Classification of Glycosaminoglycans (GAG'S)	1
1.1.1.1 Common GAG types.	1
1.1.1.2 Heterogeneity of disaccharide repeat sequences	4
1.1.2. Biological roles of GAG's	6
1.1.3. GAG properties	10
1.1.3.1 pK _a of ionizable groups	10
1.1.3.2 Flexibility of uronic acid sugar residues	11
1.1.3.3 Hydrophobic patches	12
1.1.3.4 Secondary Structure	12
1.1.3.5 Stereochemistry of charged groups	13
1.1.3.6 Binding to polycations	13
1.1.3.4 Summary of important GAG properties	15
1.2 SEPARATION OF GAG's	16
1.2.1. Ion exchange resins	17
1.2.2. Fractional solvent precipitation	18
1.2.3. Polylysine resins	18
1.2.4 Hydrophobic interactive chromatography	19
1.2.5 Bioaffinity chromatography	20
1.2.6 Summary of GAG purification procedures	21
1.3 BINDING OF GAG'S TO PROTEINS	22
1.3.1 Sequence specific binding	22
1.3.2 Protein consensus sequences for GAG binding	24
1.3.3 Conformational change of protein	26
1.3.4 Examples of GAG binding peptides	28
1.4 Scope of this study	28
CHAPTER TWO: GAG STANDARDS	33
2.1 INTRODUCTION	33
2.2 MATERIAL AND METHODS	35
2.2.1 Equipment	35
2.2.2 Chemicals	36
2.2.3 Preparative GAG fractionation procedures	36

2.2.3.1	Calcium salt ethanol fractionation	36
2.2.3.2	Calcium salt to sodium salt conversion	37
2.2.3.3	Selective precipitation of heparin	37
2.2.3.4	Alkaline copper precipitation	38
2.2.4	Characterisation of GAG samples	38
2.2.4.1	Cellulose acetate electrophoresis	38
2.2.4.2	Optical rotation measurements	40
2.2.4.3	Chondroitinase ABC and AC lyase digestion	40
2.2.4.4	C ¹³ NMR spectroscopy	41
2.2.4.5	Elemental analysis	41
2.2.4.6	Uronic acid assay	42
2.2.4.7	Dimethylmethene blue assay for GAG's	42
2.2.4.8	Intrinsic viscosity determination	43
2.2.4.9	Iduronic-2OSulphate assay	43
2.3	RESULTS AND DISCUSSION	44
2.3.1	Alkaline copper precipitation	44
2.3.2	Ethanol precipitation of calcium salts	45
2.3.3	2M KOAc, pH 5.7 precipitation	47
2.3.4	Characterisation of GAG samples	49
2.3.4.1	Enzymatic digestion	49
2.3.4.2	C ¹³ NMR Spectroscopy	53
2.3.4.3	Charge density of GAG standards	60
2.3.4.4	Iduronic 2OS levels	62
2.3.4.5	Molecular weight and molecular weight distribution . . .	63
2.4	SUMMARY OF CHAPTER	63
 CHAPTER 3: PEPTIDE SYNTHESIS		66
3.1	INTRODUCTION	66
3.2:	MATERIALS AND METHODS	69
3.2.1	Equipment	69
3.2.2	Chemicals	69
3.2.3	Quantitative ninhydrin procedure	70
3.2.4	Picrate titration of resin bound amine groups	70
3.2.5	Synthesis of K ₄ G and K ₈ G peptide resins	71
3.2.5.1	Reaction of Perloza with FmocGLYOBt	71
3.2.5.2	Coupling of the aminoacids to the resin.	71
3.2.5.3	Theoretical calculation of substitution levels	72
3.2.5.4	Amino acid analysis	72
3.2.5.5	Removal of protecting groups	73
3.2.6	Automated synthesis of K ₄ G and K ₁₂ G peptide resins	73
3.2.7	Synthesis of free peptides	73
3.2.7.1	Purification of peptides	73
3.2.8	Characterisation of purified peptides	74
3.2.8.1	Reverse phase HPLC	74
3.2.8.2	Capillary electrophoresis (C.E.)	74

3.2.8.3 Fast atom bombardment (FAB)-mass spectrometry	75
3.3 RESULTS AND DISCUSSION	75
3.3.1 K _x G Resins	75
3.3.2 Synthesis of free peptides	77
3.3.2.1 Protease C inhibitor peptide (residues 264-283)	77
3.3.2.2 Thrombospondin peptide	78
3.3.2.3 K ₈ G peptide	80
3.3.3 Capillary electrophoresis of free peptides	81
3.4 SUMMARY	83
Chapter 4: BINDING OF GAG'S TO IMMOBILISED PEPTIDE RESINS	84
4.1 INTRODUCTION	84
4.2 MATERIALS AND METHODS	87
4.2.1 Chemicals	87
4.2.2 Equipment	87
4.2.3 Preparation of immobilised polylysine resin	87
4.2.4 Binding of GAG standards to polylysine resins	88
4.2.4.1 Binding and elution experiments	88
4.2.4.2 Data analysis	90
4.2.5 GAG binding capacities of the peptide resins	90
4.2.6 Ligand displacement chromatography on PLL resin	91
4.3 RESULTS AND DISCUSSION	91
4.3.1 Immobilisation of polylysine (PLL)	91
4.3.2 Validation of relative binding strength	92
4.3.3 Binding of GAG standards to PLL-resin	93
4.3.4 Binding and elution of GAG standard from K _x G peptide resins	93
4.3.5 Comparison of the binding behaviour of the PLL-resin and K _x G resins	96
4.3.6 PLL-resin: Ligand displacement chromatography	100
4.3.7 CHAPTER SUMMARY	101
Chapter 5: SOLUTION BINDING OF GAG'S TO PEPTIDES	103
5.1 INTRODUCTION	103
5.2 MATERIALS AND METHODS	106
5.2.1 Chemicals	106
5.2.2 Equipment	106
5.2.3 Stoichiometry of GAG/peptide interaction	107
5.2.3.1 Purification of methylene blue	107
5.2.3.2 Methylene blue titration	107
5.2.3.3 Data Analysis	108
5.2.4 Secondary structure determination	109
5.2.5 Secondary structure prediction	111
5.3 RESULTS AND DISCUSSION	113
5.3.1 Hydrophobic profiles	113
5.3.2 CD conformational study	115

5.3.2.1 Calibration of the technique	115
5.3.2.2 Polylysine/ GAG interaction	118
5.3.2.3 Thrombospondin peptide	123
5.3.2.4.1: PCI peptide	124
5.3.2.4.2 Fine structure of heparin	127
5.3.3.1 Stoichiometry of GAG- peptide binding	129
5.3.3.2 Stoichiometry of GAG/lysine interaction	130
5.3.3.3 A comparison of binding stoichiometry: solution versus solid phase	132
5.4 CHAPTER SUMMARY	132
5.4.1 PLL/GAG interaction	132
5.4.2 GAG/peptide interaction	133
Chapter 6: A REEXAMINATION OF PUBLISHED WORK	134
6.0 INTRODUCTION	134
6.1 GAG binding sites on proteins	135
6.1.1 Chi squared test	135
6.1.2 Cardin and Weintraub's consensus sequences	136
6.1.3 Sobel's consensus sequence	139
6.1.4 Margalit et al's GAG binding consensus sequence	141
6.1.5 Hyaluronan binding site	142
6.1.6 Ligands for sulphate binding	142
6.1.7 Summary of consensus sequences	143
6.2 Conformational change of peptide on binding GAG's	144
6.2.1 Importance of the conformational change	144
6.2.2 PLL/GAG interaction	145
6.2.3 Peptide/GAG interactions	146
6.2.3.1 A stereochemical model for GAG binding	149
6.2.3.2 Biological binding behaviour of peptides	150
6.2.3.3 Discussion of the model	154
6.3 Binding strength of GAG/peptide interaction	155
6.4.1 Specificity of peptide/GAG interactions	159
6.4.2 ATIII/heparin interaction	160
6.4.3 Peptide affinity columns	164
6.4.4 Energetics of peptide/heparin interaction	164
6.4.5 Summary	165
6.5 Sequence specific binding	165
6.6 CHAPTER SUMMARY	167
CHAPTER 7: CONCLUSION	169
7.1 INTRODUCTION	169
7.2 GAG STANDARDS	170
7.3 GAG BINDING BEHAVIOUR OF PLL RESINS	171
7.4 GAG BINDING PETIDES	172

7.5 MODELS OF THE GAG/PEPTIDE INTERACTION	174
7.5.1 Stereochemical model	174
7.5.2 Consensus sequence model	176
7.5.3 Implications of the models	176
7.6 OUTLINE OF FUTURE WORK	177
Appendix 1: Supplementary material to Chapter 1.	179
A1.1: GAG properties	179
A1.2 Heparan sulphate proteoglycans (HSPG) and amyloidoses	180
A1.2.1 Alzheimer's Disease	182
A1.2.2 AA Amyloidosis	183
A1.2.3 Prion disorders	183
Appendix 2: Supplementary material to Chapters 2 and 3	185
A2.1 Worked examples of viscosity molecular weight determination	185
A2.2 Worked examples of calculation of substitution menu	185
Appendix 3: Supplementary material to Chapter 4	187
A3.1 Data analysis of GAG binding to ion exchange resins	189
A3.2 GAG binding to peptide resins	189
A3.3 Sample calculation of stoichiometry of GAG binding to polylysine resin	192
Appendix 4: Supplementary material to Chapter 5	194
A4.1 Calculation of hydrophobic moments	194
A4.2 CD spectral data for peptide/GAG complexes	194
A4.3 Sample calculation for stoichiometry of solution binding	198
Appendix 5: Supplementary information to Chapter 6	200
A5.1 Distribution of acidic, aromatic and basic residues within consensus sequences	200
A5.1.1 Cardin and Weintraub type I	200
A5.1.2 Cardin and Weintraub's type II consensus sequence	201
A5.1.3 Sobel's et al consensus sequence	202
A5.2 Preferred ligand for sulphate binding	202
A5.3 Worked examples for stereochemical model	205
A5.3.1 Peptides with no acidic residues	205
A5.3.2 Peptides containing acidic residues	207
A5.3.3: Peptide data for stereochemical model	208
A5.4 Peptide data for consensus sequence binding model	210
A5.5: Specificity of ATIII peptide heparin interaction	210

List of Figures

Figure 1.1: Structures of monosaccharide units in GAG's	3
Figure 2.1: Electrophoretic analysis of Calcium ppt Technique	46
Figure 2.2: Electrophoretic analysis of GAG fractionation procedures	48
Figure 2.3a: Chondroitinase ABC lyase digestion	51
Figure 2.3b: Chondroitinase AC lyase digestion	51
Figure 2.4: Electrophoretic analysis of enzymatically degraded GAG standards	52
Figure 2.5: Chondroitin and Dermatan sulphate C ¹³ NMR spectra	55
Figure 2.6: C ¹³ NMR spectra of slow and fast heparin	58
Figure 2.7: Intrinsic viscosity determination	64
Figure 3.1: HPLC profiles of PCI peptide	78
Figure 3.2: CE profiles of purified PCI peptide	79
Figure 3.3: HPLC profiles of Thrombospondin peptide	79
Figure 3.4: CE profiles of purified Thrombospondin peptide	80
Figure 3.5: HPLC profiles of K ₈ G peptide	81
Figure 3.6: CE profiles of purified K ₈ G peptide	82
Figure 4.1: Shape of gradients used in resin binding experiments	89
Figure 4.2: Elution of GAG standards from PLL-resin	95
Figure 4.3: Typical profile for PLL-resin with ligand displacement chromatography	101
Figure 5.1: Hydrophobic moment profiles for the peptides	114
Figure 5.2: CD spectra of GAG standards	117
Figure 5.3: CD spectra of long PLL/GAG complexes	119
Figure 5.4: CD spectra of short PLL/GAG complexes	120
Figure 5.5: CD spectra for K ₈ G/GAG complexes	122
Figure 5.6: CD spectra of Thrombospondin/GAG complexes	123
Figure 5.7: CD spectra of PCI peptide/GAG complexes	125
Figure 5.8: Salt dissociation curves for PCI peptide/GAG complexes	127
Figure 5.9: Methylene Blue titration curve	129
Figure 6.1: Proposed origin of Sobel's consensus sequence	140
Figure 6.2: Salt strength binding correlations	157

Figure A3.1: Cumulative Elution of GAG's from Dowex 1X2 resin	187
Figure A3.2: Cumulative Elution of GAG's from ECTEOLA-cellulose	188

List of Tables

Table 1.1: Classification of glycosaminoglycans	2
Table 1.2: Summary of Gelmans solution binding experiments	15
Table 1.3: Sequences specific binding sites on GAG's	23
Table 1.4: Proposed consensus sequences for Heparin binding	25
Table 1.5: Influence of Polysaccharide binding on peptide conformation	29
Table 1.6: Free peptides synthesized as part of this thesis	31
Table 2.1: Constants for Mark-Houwink Equation	35
Table 2.2: Typical Optical rotations of GAG classes	40
Table 2.3: Preparative precipitation of calcium salts	46
Table 2.4: Heparin fractionation	48
Table 2.5: Assignment of C ¹³ Peaks for dermatan and chondroitin sulphate	56
Table 2.6: Assignment of C ¹³ Peaks for Fast and Slow heparin	61
Table 2.7: Charge density and percentage sulphate and nitrogen of GAG's	62
Table 2.8: Epoxidation reaction results	62
Table 2.9: Summary of viscosity results for GAG standards	64
Table 2.10: Summary of the properties of the GAG standards	65
Table 3.1: Biolynx continuous flow peptide synthesizer synthesis cycle	72
Table 3.2: Run parameters for Capillary electrophoresis	75
Table 3.3: Analytical data on K _x G resins	76
Table 3.4: Deprotection of K _x G Resins	77
Table 3.5: Analytical data for cleavable K ₈ G peptide	80
Table 3.6: Comparison of the CE buffers performance	82
Table 4.1: Binding behaviour of GAG's on ion exchange resin.	85
Table 4.2: Details of gradients used in resin binding experiments	90
Table 4.3: Substitution level of PLL resin	92
Table 4.4: Validation of relative binding strength for K ₄ G resin	93
Table 4.5: Elution of GAG standards from PLL-resin	94
Table 4.6: Summary of elution experiment on peptide resins	94

Table 4.7: Comparison of GAG binding	97
Table 4.8: Stoichiometry of GAG binding to polylysine resins	99
Table 5.1: Set up parameters for CD analysis	110
Table 5.2: Amphipathic indexes of GAG binding peptides	114
Table 5.3: Optical rotation of Dermatan sulphate and Heparin at 222 nm	116
Table 5.4: Secondary structure elements for long PLL/GAG complexes	119
Table 5.5: Secondary structure elements for short PLL/GAG complexes	120
Table 5.6: Comparison of induced helix for PLL GAG binding	121
Table 5.7: Secondary structure elements for K ₈ G/GAG complexes	122
Table 5.8: Secondary structure elements of Thrombospondin/GAG complexes	124
Table 5.9: Secondary structure elements of PCI peptide/GAG complexes	124
Table 5.10: Relative rate increase of GAG for PCI inhibition	126
Table 5.11: Time course of heparin binding	130
Table 5.12: A comparison of the stoichiometry of the GAG/polylysine interaction.	131
Table 5.13: PLL chain binding behaviour solution and resin bound	132
Table 6.1: Cardin's Type I consensus sequence	137
Table 6.2: Cardin's type II consensus sequence	138
Table 6.3: Distribution of basic residues in Sobel's consensus sequence	139
Table 6.4: Comparison of basic amino acid tendencies	140
Table 6.5: A comparison of induced helix and disaccharide repeat distance	146
Table 6.6: Evaluation of the model	151
Table 6.7: Summary of Camejo et al's results	152
Table 6.8: FN-C/HII peptide results	153
Table 6.9: Summary of peptides for used in the salt strength correlation	158
Table 6.10: Summary of peptide modelling of ATIII/heparin interaction	162
Table 6.11: Peptide modelling of the specificity of the ATIII/heparin interaction	164
Table 6.12: A comparison of the two GAG binding models	168
Table A1.1: Properties of the GAG's Used by Gelman	179
Table A1.2: Elution behaviour of GAG's on Suzuki's PLL resin	179
Table A1.3: Ionizing groups per disaccharide units of GAG's	180

Table A2.1: Data processing for viscosity determination	185
Table A2.2: Substitution menu for K ₄ G	186
Table A3.1: Binding of GAG's to two ion exchange resins	188
Table A3.2: K ₄ G resin ECONO system runs	189
Table A3.3: K ₄ G resin FPLC runs	189
Table A3.4: K ₈ G resin FPLC runs	190
Table A3.5: K ₁₂ G resin FPLC runs	191
Table A3.6: PLL resin FPLC runs	192
Table A4.1: Sample calculation of hydrophobic moment at 80° degree's for PCI peptide	195
Table A4.2: PLL (long)/GAG interaction	196
Table A4.3: PLL (short)/GAG interaction	196
Table A4.4: K ₈ G/GAG interaction	197
Table A4.5: PCI peptide/GAG interactions	197
Table A4.6: Thrombospondin peptide/GAG interaction	197
Table A5.1: Distribution of residues within type I consensus sequences,	200
Table A5.2: Distribution of the outcomes at position 2,3 and 4	201
Table A5.3: Distribution of the residues within the type II consensus sequence	202
Table A5.4: distribution of the residues within Sobel's Consensus sequence	203
Table A5.5: Preferred ligands for sulphate binding	204
Table A5.6: Preference Among Basic Ligands	205
Table A5.7: Multiples of Disaccharide repeat distances for GAG's	206
Table A5.8: Distances between basic residues in an alpha helical conformation	206
Table A5.9: Distances between basic residues in a beta strand conformation	206
Table A5.10: Distances between acidic and basic residues	207
Table A5.11: Distances between basic residues in a alpha helical conformation	207
Table A5.12: Distances between basic residues in a beta strand conformation	208
Table A5.13: Summary of the peptides used in the stereochemical model	209
Table A5.14: Summary of peptides used in the consensus sequence model	210
Table A5.15: Data treatment for Bae et al's peptides	211

Abbreviations

α	Alpha helix
β	Beta sheet
C ¹³	Carbon thirteen
CS	Chondroitin sulphate
C4S	Chondroitin-4-sulphate
C6S	Chondroitin-6-sulphate
CD	Circular dichroism
DS	Dermatan sulphate
GAG	Glycosaminoglycan
Gal	Galactose
GalN	Galactosamine
GalNAc	N-acetyl-galactosamine
GlcN	Glucosamine
GlcNAc	Nacetylglucosamine
GlcNS	Glucosamine-Nsulphate
GlcNS(5S)	Glucosamine-Nsulphate-5O sulphate
GlcN(6SO ₃)	Glucosamine-Nsulphate-6O sulphate
GluA	Glucuronic acid
Hep	Heparin
HexA	Hexuronic acid
HS	Heparan sulphate
Ido2S	Iduronic acid-2O sulphate
IdoA	Iduronic acid
N _{eff}	Number of theoretical plates
PLA	Poly-L-arginine
PLL	Poly-L-lysine
R	Random coil